Verge Genomics has secured its largest deal yet, linking up with AstraZeneca’s rare disease division Alexion in a deal worth up to $882 million.
The San Francisco biotech said Friday morning that the four-year deal focuses on multiple undisclosed rare neurodegenerative and neuromuscular diseases. AstraZeneca will pay Verge $42 million…
Click here to view original post
